Stefan Klostermann
Overview
Explore the profile of Stefan Klostermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steininger T, Ottl V, Franken L, Frank C, Ohland P, Lopez Ferreiro M, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941089
In the dynamic field of gene therapy, recombinant adeno-associated viruses (rAAVs) have become leading viral vectors due to their safety, long-term expression, and wide-ranging cell and tissue tropism. With numerous...
2.
Bauer N, Boettger M, Papadaki S, Leitner T, Klostermann S, Kettenberger H, et al.
Front Bioeng Biotechnol
. 2024 Nov;
12:1414408.
PMID: 39530057
We present a detailed mass spectrometric analysis of three 2 + 1 T-cell bispecific monoclonal antibodies (TCB mAbs), where an unexpected +15.9950 Da mass shift in tryptic peptides was observed....
3.
Elias S, Wrzodek C, Deane C, Tissot A, Klostermann S, Ros F
Front Bioinform
. 2024 Apr;
3:1286883.
PMID: 38651055
Antibodies are generated with great diversity in nature resulting in a set of molecules, each optimized to bind a specific target. Taking advantage of their diversity and specificity, antibodies make...
4.
Ros F, Offner S, Klostermann S, Thorey I, Niersbach H, Breuer S, et al.
MAbs
. 2020 Nov;
12(1):1846900.
PMID: 33228444
Transgenic animals incorporating human antibody genes are extremely attractive for drug development because they obviate subsequent antibody humanization procedures required for therapeutic translation. Transgenic platforms have previously been established using...
5.
Jost C, Darowski D, Challier J, Pulko V, Hanisch L, Xu W, et al.
MAbs
. 2020 Nov;
12(1):1840709.
PMID: 33136521
T-cell bispecific antibodies (TCBs) are a novel class of engineered immunoglobulins that unite monovalent binding to the T-cell receptor (TCR) CD3e chain and bivalent binding to tumor-associated antigens in order...
6.
Tyshchuk O, Gstottner C, Funk D, Nicolardi S, Frost S, Klostermann S, et al.
MAbs
. 2019 Jul;
11(7):1219-1232.
PMID: 31339437
Biotherapeutics may contain a multitude of different post-translational modifications (PTMs) that need to be assessed and possibly monitored and controlled to ensure reproducible product quality. During early development of biotherapeutics,...
7.
Marks C, Nowak J, Klostermann S, Georges G, Dunbar J, Shi J, et al.
Bioinformatics
. 2017 Apr;
33(9):1346-1353.
PMID: 28453681
Motivation: Loops are often vital for protein function, however, their irregular structures make them difficult to model accurately. Current loop modelling algorithms can mostly be divided into two categories: knowledge-based,...
8.
Nowak J, Baker T, Georges G, Kelm S, Klostermann S, Shi J, et al.
MAbs
. 2016 Mar;
8(4):751-60.
PMID: 26963563
Complementarity-determining regions (CDRs) are antibody loops that make up the antigen binding site. Here, we show that all CDR types have structurally similar loops of different lengths. Based on these...
9.
Bujotzek A, Fuchs A, Qu C, Benz J, Klostermann S, Antes I, et al.
MAbs
. 2015 Jul;
7(5):838-52.
PMID: 26176812
Knowledge of the 3-dimensional structure of the antigen-binding region of antibodies enables numerous useful applications regarding the design and development of antibody-based drugs. We present a knowledge-based antibody structure prediction...
10.
Sydow J, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Molhoj M, et al.
PLoS One
. 2014 Jun;
9(6):e100736.
PMID: 24959685
Monoclonal antibodies (mAbs) and proteins containing antibody domains are the most prevalent class of biotherapeutics in diverse indication areas. Today, established techniques such as immunization or phage display allow for...